Contribution of PET CT to 18 F FDG in bronchopulmonary cancer

Bronchopulmonary cancer represents a real public health problem. The aim of our work is to demonstrate the additional contribution of positron emission tomography coupled with 18F-fluoro deoxy-glucose computed tomography (18FDG PET-CT) both locally and remotely in optimizing the management of non-small cell bronchopulmonary cancers. In the initial preoperative workup PET-CT allowed us to modify the stage in 69% of cases with up staging in 6 patients and down staging in 3 patients. In addition PET-CT allowed us to find a suspicious hypermetabolic breast nodule in one case. For recurrence assessment PET-CT confirmed the diagnosis of recurrence in 7 cases and invalidated it in the remaining 3 cases. For pulmonary nodule characterization PET-CT allowed us to find suspicious pulmonary hypermetabolism in 5 cases associated with bone involvement in one case mediastinal lymph nodes in 4 cases and suspicious thyroid hypermetabolism in one case.